June 3 ASCO Quick Takes: ORR of 32% for Celgene's iberdomide in MM; plus Five Prime, Iovance and more

Celgene highlights iberdomide data for MM at ASCO
Celgene Corp. (NASDAQ:CELG) presented data at ASCO Sunday showing that iberdomide (CC-220) plus dexamethasone led to an overall response rate (ORR) of 32%, including 17 partial responses and two very good partial responses, among 66 evaluable patients with relapsed and refractory multiple myeloma in the Phase I/II CC-220-MM-001 trial. Iberdomide is a next-generation oral immunomodulator that targets cereblon

Read the full 656 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE